Kolon TissueGene (950160) recorded a lower limit for the third consecutive trading day in early trading on the 23rd, with its stock price falling to the 20,000-won range.

As of 9:02 a.m. on the same day, Kolon TissueGene is trading at 21,050 won, down 9,000 won (29.95%) from the previous trading day. Following the 21st and 22nd, the stock has now dropped to the price limit for three consecutive trading days through today, showing a significant contraction in investor sentiment. After going straight to the lower limit immediately after the market open, sell orders have continued to pile up, keeping the stock at the lower limit level, and the share price has plummeted to the 20,000-won range in just three days.

This sharp decline is interpreted as the continued impact of the initial results from the U.S. Phase 3 clinical trial of TG-C, a cell gene therapy for osteoarthritis, which failed to achieve statistical significance compared to a placebo.

Market analysts note that given the continued sharp stock price volatility in the short term, it is necessary to monitor future additional disclosures, follow-up announcements related to the clinical trial, and changes in investor sentiment.

[※ This article is not an investment solicitation, and the final judgment and responsibility for investments lie with the investor.]